{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:15:24Z","timestamp":1788830124301,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03688-4","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:23:21Z","timestamp":1767104601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology"],"prefix":"10.1186","volume":"27","author":[{"given":"Francesca","family":"Burlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Dalla","family":"Zuanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Curci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Taddio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"1","key":"3688_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-025-01122-2","volume":"23","author":"X Peng","year":"2025","unstructured":"Peng X, Liu Q, Lin L, Dong L. The incidence and risk factors of uveitis in children with juvenile idiopathic arthritis (JIA): a meta -analysis and literature review. Pediatr Rheumatol Online J. 2025;23(1):71. https:\/\/doi.org\/10.1186\/s12969-025-01122-2.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"3688_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1080\/09273948.2023.2279682","volume":"31","author":"J Huard","year":"2023","unstructured":"Huard J, Mihailescu SD, Muraine M, Raymond S, Grall Lerosey M, Gueudry J. Effectiveness and safety of weekly adalimumab for non-infectious chronic anterior uveitis in children. Ocul Immunol Inflamm. 2023;31(10):2039\u201349. https:\/\/doi.org\/10.1080\/09273948.2023.2279682.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"3688_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1089\/jop.2021.0098","volume":"38","author":"S Gupta","year":"2022","unstructured":"Gupta S, Shyamsundar K, Agrawal M, Vichare N, Biswas J. Current knowledge of biologics in treatment of noninfectious uveitis. J Ocul Pharmacol Ther. 2022;38(3):203\u201322. https:\/\/doi.org\/10.1089\/jop.2021.0098.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"3688_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/acr.24859","volume":"75","author":"RHJ Verstegen","year":"2023","unstructured":"Verstegen RHJ, Shrader P, Balevic SJ, Beukelman T, Correll C, Dennos A, et al. Dosing variation at initiation of adalimumab and etanercept and clinical outcomes in juvenile idiopathic arthritis: a Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care Res (Hoboken). 2023;75(2):410\u201322. https:\/\/doi.org\/10.1002\/acr.24859.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"3688_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40272-020-00382-7","volume":"22","author":"ZH Temrikar","year":"2020","unstructured":"Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs. 2020;22(2):199\u2013216. https:\/\/doi.org\/10.1007\/s40272-020-00382-7.","journal-title":"Paediatr Drugs"},{"key":"3688_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3389\/fphar.2019.00637","volume":"10","author":"T Giani","year":"2019","unstructured":"Giani T, De Masi S, Maccora I, Tirelli F, Simonini G, Falconi M, et al. The influence of overweight and obesity on treatment response in juvenile idiopathic arthritis. Front Pharmacol. 2019;10:637. https:\/\/doi.org\/10.3389\/fphar.2019.00637.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3688_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40272-024-00633-x","volume":"26","author":"K Meesters","year":"2024","unstructured":"Meesters K, Balbas-Martinez V, Allegaert K, Downes KJ, Michelet R. Personalized dosing of medicines for children: a primer on pediatric pharmacometrics for clinicians. Paediatr Drugs. 2024;26(4):365\u201379. https:\/\/doi.org\/10.1007\/s40272-024-00633-x.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"3688_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/acr.23610","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Lo MS, Henderson LA, Lerman MA, Abramson L, Cooper AM, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-Associated and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2019;71(4):482\u201391. https:\/\/doi.org\/10.1002\/acr.23610.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3688_CR9","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1097\/RHU.0000000000001707","volume":"28","author":"JE Roberts","year":"2022","unstructured":"Roberts JE, Nigrovic PA, Lo MS, Chang MH. Weekly adalimumab, an effective alternative for refractory uveitis in children. J Clin Rheumatol. 2022;28(1):e301-4. https:\/\/doi.org\/10.1097\/RHU.0000000000001707.","journal-title":"J Clin Rheumatol"},{"issue":"7\u20138","key":"3688_CR10","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","volume":"29","author":"P Liberman","year":"2021","unstructured":"Liberman P, Berkenstock MK, Burkholder BM, Chaon BC, Thorne JE. Escalation to weekly adalimumab for the treatment of ocular inflammation. Ocul Immunol Inflamm. 2021;29(7\u20138):1564\u20138. https:\/\/doi.org\/10.1080\/09273948.2020.1749857.","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"3688_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/acr.24963","volume":"75","author":"I Foeldvari","year":"2023","unstructured":"Foeldvari I, Maccora I, Petrushkin H, Rahman N, Anton J, de Boer J, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2023;75(5):975\u201382. https:\/\/doi.org\/10.1002\/acr.24963.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3688_CR12","doi-asserted-by":"crossref","unstructured":"Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366\u201374.","DOI":"10.1002\/art.34373"},{"key":"3688_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajo.2021.03.055","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for juvenile idiopathic arthritis-associated chronic anterior uveitis. Am J Ophthalmol. 2021;228:192\u20137. https:\/\/doi.org\/10.1016\/j.ajo.2021.03.055.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3688_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3688_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00928-2","volume":"21","author":"JL Dehoorne","year":"2023","unstructured":"Dehoorne JL, Groth H, Carl\u00e9 E, De Schrijver I, Sys C, Delbeke P, et al. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment. Pediatr Rheumatol Online J. 2023;21(1):148. https:\/\/doi.org\/10.1186\/s12969-023-00928-2.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"3688_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/MIB.0000000000000327","volume":"21","author":"S Sharma","year":"2015","unstructured":"Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\u2019s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21(4):783\u201392. https:\/\/doi.org\/10.1097\/MIB.0000000000000327.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"3688_CR17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/art.39169","volume":"67","author":"M Jani","year":"2015","unstructured":"Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, et al. Clinical utility of random anti\u2013tumor necrosis factor drug\u2013level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheum. 2015;67(8):2011\u20139. https:\/\/doi.org\/10.1002\/art.39169.","journal-title":"Arthritis Rheum"},{"key":"3688_CR18","doi-asserted-by":"publisher","first-page":"646671","DOI":"10.3389\/fped.2021.646671","volume":"9","author":"M Lucaf\u00f2","year":"2021","unstructured":"Lucaf\u00f2 M, Curci D, Bramuzzo M, Alvisi P, Martelossi S, Silvestri T, et al. Serum adalimumab levels after induction are associated with long-term remission in children with inflammatory bowel disease. Front Pediatr. 2021;9:646671. https:\/\/doi.org\/10.3389\/fped.2021.646671.","journal-title":"Front Pediatr"},{"issue":"9","key":"3688_CR19","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/art.21266","volume":"52","author":"Z Tutuncu","year":"2005","unstructured":"Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum. 2005;52(9):2693\u20136. https:\/\/doi.org\/10.1002\/art.21266.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3688_CR20","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/art.21389","volume":"52","author":"CA Wallace","year":"2005","unstructured":"Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554\u201362. https:\/\/doi.org\/10.1002\/art.21389.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3688_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/FTD.0000000000000494","volume":"40","author":"SE Berends","year":"2018","unstructured":"Berends SE, Strik AS, Van Selm JC, L\u00f6wenberg M, Ponsioen CY, D\u02bcHaens GR, et al. Explaining interpatient variability in adalimumab pharmacokinetics in patients with crohn\u2019s disease. Ther Drug Monit. 2018;40(2):202\u201311. https:\/\/doi.org\/10.1097\/FTD.0000000000000494.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"3688_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40272-024-00629-7","volume":"26","author":"A Nassar-Sheikh Rashid","year":"2024","unstructured":"Nassar-Sheikh Rashid A, Hooijberg F, Bergkamp SC, Gruppen MP, Kuijpers TW, Nurmohamed M, et al. Population pharmacokinetics of adalimumab in juvenile idiopathic arthritis patients: a retrospective cohort study using clinical care data. Paediatr Drugs. 2024;26(4):441\u201350. https:\/\/doi.org\/10.1007\/s40272-024-00629-7.","journal-title":"Paediatr Drugs"},{"issue":"42","key":"3688_CR23","doi-asserted-by":"publisher","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","volume":"22","author":"U Billmeier","year":"2016","unstructured":"Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300\u201313. https:\/\/doi.org\/10.3748\/wjg.v22.i42.9300.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3688_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s10067-018-4057-7","volume":"37","author":"A Marino","year":"2018","unstructured":"Marino A, Real-Fern\u00e1ndez F, Rovero P, Giani T, Pagnini I, Cimaz R, et al. Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol. 2018;37(5):1407\u201311. https:\/\/doi.org\/10.1007\/s10067-018-4057-7.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3688_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.mib.0000194185.69800.07","volume":"12","author":"C Shen","year":"2006","unstructured":"Shen C, Van Assche G, Rutgeerts P, Ceuppens JL. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis. 2006;12(1):22\u20138. https:\/\/doi.org\/10.1097\/01.mib.0000194185.69800.07.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"3688_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04065.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"3688_CR27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.14309\/ajg.0000000000002741","volume":"119","author":"DR Ebach","year":"2024","unstructured":"Ebach DR, Jester TW, Galanko JA, Firestine AM, Ammoury R, Cabrera J, et al. High body mass index and response to anti-tumor necrosis factor therapy in pediatric crohn\u2019s disease. Am J Gastroenterol. 2024;119(6):1110\u20136. https:\/\/doi.org\/10.14309\/ajg.0000000000002741.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"3688_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1097\/MEG.0000000000002250","volume":"33","author":"T Greener","year":"2021","unstructured":"Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, et al. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn\u2019s disease patients. Eur J Gastroenterol Hepatol. 2021;33(10):1274\u20139. https:\/\/doi.org\/10.1097\/MEG.0000000000002250.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"3688_CR29","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1053\/j.gastro.2022.02.033","volume":"162","author":"J Pan\u00e9s","year":"2022","unstructured":"Pan\u00e9s J, Colombel JF, D\u2019Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. Gastroenterology. 2022;162(7):1891\u2013910. https:\/\/doi.org\/10.1053\/j.gastro.2022.02.033.","journal-title":"Gastroenterology"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03688-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:23:22Z","timestamp":1767104602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3688"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03688-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"27 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Board Review at the IRCCS Burlo Garofolo (RC 23\/2022). All parents of children involved in the study gave the consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all parents of children involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}